View ValuationAriBioLabLtd 将来の成長Future 基準チェック /06現在、 AriBioLabLtdの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長24.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 29New major risk - Revenue and earnings growthEarnings have declined by 0.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Revenue is less than US$1m (₩332m revenue, or US$222k). Minor Risk Market cap is less than US$100m (₩99.5b market cap, or US$66.6m).お知らせ • May 15CHA Vaccine Research Institute announced that it expects to receive KRW 4 billion in fundingCHA Vaccine Research Institute has announced a private placement of Series 6 Unregistered Interest Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 4,000,000,000 on May 14, 2026. The transaction involves the new investor participation of Hanwool P&I Co., Ltd. for KRW 4,000,000,000. The bonds are 100% convertible into 1,246,105 common shares of the company at a conversion price value of KRW 3,210 and carry interest rate of 2% and maturity interest rate of 8%. The conversion billing period starts from June 05, 2027 to May 05, 2029.The transaction has been approved by the board of directors of the company. The transaction is subject to 1 year hold period. The bonds have a maturity date of June 05, 2029. The transaction is expected to close on June 05, 2026.New Risk • Apr 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (₩159m revenue, or US$107k). Minor Risk Market cap is less than US$100m (₩92.7b market cap, or US$62.6m).New Risk • Mar 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩159m revenue, or US$106k). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (₩142.4b market cap, or US$95.1m).お知らせ • Mar 20CHA Vaccine Research Institute announced that it expects to receive KRW 4.999999 billion in fundingCHA Vaccine Research Institute announced a private placement to issue 1,834,862 common shares at an issue price of KRW 2,725 for gross proceeds of KRW 4,999,998,950 on March 18, 2026. The transaction includes participation from new investor, Dream High Holdings Co., Ltd. The transaction will happen through third party allocation. The transaction has been approved at board of director meeting of the company. The issue date will be May 29, 2026. The shares are subject to 1 year lockup.お知らせ • Mar 12CHA Vaccine Research Institute, Annual General Meeting, Mar 25, 2026CHA Vaccine Research Institute, Annual General Meeting, Mar 25, 2026, at 09:01 Tokyo Standard Time. Location: conference hall, 808, seongnam-daero, bundang-gu, gyeonggi-do, seongnam South Korea分析記事 • Nov 21Does CHA Vaccine Research Institute (KOSDAQ:261780) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Apr 02Is CHA Vaccine Research Institute (KOSDAQ:261780) Using Debt Sensibly?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Mar 12CHA Vaccine Research Institute, Annual General Meeting, Mar 26, 2025CHA Vaccine Research Institute, Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 808, seongnam-daero, bundang-gu, gyeonggi-do, seongnam South Korea分析記事 • Dec 05Is CHA Vaccine Research Institute (KOSDAQ:261780) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Sep 05+ 1 more updateCHA Vaccine Research Institute announced that it has received KRW 10 billion in funding from Mezzanine Growth New Technology Investment Fund, NH Investment & Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd. and another investorOn September 5, 2024, CHA Vaccine Research Institute closed the transaction.分析記事 • Aug 12Is CHA Vaccine Research Institute (KOSDAQ:261780) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Jan 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩134.2b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩294m revenue, or US$219k). Minor Risk Market cap is less than US$100m (₩134.2b market cap, or US$99.7m).New Risk • Oct 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩131.0b (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩294m revenue, or US$217k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩131.0b market cap, or US$96.8m).New Risk • Jun 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.8b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 70% over the past year. Revenue is less than US$1m (₩184m revenue, or US$140k). Minor Risk Market cap is less than US$100m (₩130.8b market cap, or US$99.4m). このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、AriBioLabLtd は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A261780 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026332-15,544-10,662-10,588N/A12/31/2025159-16,044-11,173-11,017N/A9/30/2025159-14,251-11,292-11,093N/A6/30/2025159-12,369-10,990-10,734N/A3/31/20250-11,295-8,550-8,339N/A12/31/2024371-10,138-8,330-8,096N/A9/30/2024371-4,260-6,356-6,171N/A6/30/2024371-4,457-5,939-5,823N/A3/31/2024543-1,472-5,865-5,717N/A12/31/2023294-1,749-5,584-5,293N/A9/30/2023294-5,029-6,654-6,296N/A6/30/2023294-4,602-6,805-6,175N/A3/31/2023184-6,826-6,301-5,687N/A12/31/2022179-6,715-5,636-5,189N/A9/30/2022179-18,877-6,732-6,227N/A6/30/2022179-18,806-5,784-5,549N/A3/31/2022617-18,410-5,482-5,092N/A12/31/2021500-18,420-5,423-4,740N/A9/30/2021523-7,014-3,951-3,391N/A6/30/2021547-7,731-4,169-3,606N/A3/31/202162-7,005-4,414-4,003N/A12/31/202078-6,240-4,008-3,954N/A12/31/2019126-2,980N/A-3,093N/A12/31/2016173-1,404N/A-696N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A261780の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A261780の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A261780の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A261780の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A261780の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A261780の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 22:49終値2026/06/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AriBioLab Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 29New major risk - Revenue and earnings growthEarnings have declined by 0.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Revenue is less than US$1m (₩332m revenue, or US$222k). Minor Risk Market cap is less than US$100m (₩99.5b market cap, or US$66.6m).
お知らせ • May 15CHA Vaccine Research Institute announced that it expects to receive KRW 4 billion in fundingCHA Vaccine Research Institute has announced a private placement of Series 6 Unregistered Interest Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 4,000,000,000 on May 14, 2026. The transaction involves the new investor participation of Hanwool P&I Co., Ltd. for KRW 4,000,000,000. The bonds are 100% convertible into 1,246,105 common shares of the company at a conversion price value of KRW 3,210 and carry interest rate of 2% and maturity interest rate of 8%. The conversion billing period starts from June 05, 2027 to May 05, 2029.The transaction has been approved by the board of directors of the company. The transaction is subject to 1 year hold period. The bonds have a maturity date of June 05, 2029. The transaction is expected to close on June 05, 2026.
New Risk • Apr 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (₩159m revenue, or US$107k). Minor Risk Market cap is less than US$100m (₩92.7b market cap, or US$62.6m).
New Risk • Mar 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩159m revenue, or US$106k). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (₩142.4b market cap, or US$95.1m).
お知らせ • Mar 20CHA Vaccine Research Institute announced that it expects to receive KRW 4.999999 billion in fundingCHA Vaccine Research Institute announced a private placement to issue 1,834,862 common shares at an issue price of KRW 2,725 for gross proceeds of KRW 4,999,998,950 on March 18, 2026. The transaction includes participation from new investor, Dream High Holdings Co., Ltd. The transaction will happen through third party allocation. The transaction has been approved at board of director meeting of the company. The issue date will be May 29, 2026. The shares are subject to 1 year lockup.
お知らせ • Mar 12CHA Vaccine Research Institute, Annual General Meeting, Mar 25, 2026CHA Vaccine Research Institute, Annual General Meeting, Mar 25, 2026, at 09:01 Tokyo Standard Time. Location: conference hall, 808, seongnam-daero, bundang-gu, gyeonggi-do, seongnam South Korea
分析記事 • Nov 21Does CHA Vaccine Research Institute (KOSDAQ:261780) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Apr 02Is CHA Vaccine Research Institute (KOSDAQ:261780) Using Debt Sensibly?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Mar 12CHA Vaccine Research Institute, Annual General Meeting, Mar 26, 2025CHA Vaccine Research Institute, Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 808, seongnam-daero, bundang-gu, gyeonggi-do, seongnam South Korea
分析記事 • Dec 05Is CHA Vaccine Research Institute (KOSDAQ:261780) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Sep 05+ 1 more updateCHA Vaccine Research Institute announced that it has received KRW 10 billion in funding from Mezzanine Growth New Technology Investment Fund, NH Investment & Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd. and another investorOn September 5, 2024, CHA Vaccine Research Institute closed the transaction.
分析記事 • Aug 12Is CHA Vaccine Research Institute (KOSDAQ:261780) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Jan 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩134.2b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩294m revenue, or US$219k). Minor Risk Market cap is less than US$100m (₩134.2b market cap, or US$99.7m).
New Risk • Oct 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩131.0b (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩294m revenue, or US$217k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩131.0b market cap, or US$96.8m).
New Risk • Jun 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.8b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 70% over the past year. Revenue is less than US$1m (₩184m revenue, or US$140k). Minor Risk Market cap is less than US$100m (₩130.8b market cap, or US$99.4m).